Processa Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring at the 2026 Annual Meeting of Shareholders held on July 30, 2026. The filing covers corporate governance actions, including the election of directors, the approval of an equity incentive plan amendment, the ratification of the independent auditor, and an advisory vote on executive compensation.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder voting outcomes and corporate governance matters.
Material Changes and Voting Results
Shareholders representing at least one-third of the voting power attended the meeting, constituting a quorum. The following proposals were approved:
- Director Elections: All six nominees (Justin Yorke, George Ng, Khoso Baluch, James Neal, Geraldine Pannu, and Dr. David Young) were elected. Each received over 698,000 "For" votes with zero "Against" votes.
- Incentive Plan Amendment: Shareholders approved an amendment to the 2019 Omnibus Incentive Plan to increase the number of shares available for issuance by 200,000 shares. The vote was 579,877 "For" versus 152,958 "Against".
- Auditor Ratification: Cherry Bekaert, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 1,541,664 "For" versus 12,770 "Against".
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 640,726 "For" votes versus 89,886 "Against" votes.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors. It references the definitive Proxy Statement filed on June 18, 2026, for a detailed description of the Incentive Plan.
Key Facts for Investor Verification
- Verify the impact of the 200,000 share increase in the Omnibus Incentive Plan on potential future dilution.
- Review the full text of the Amended and Restated 2019 Omnibus Incentive Plan (Exhibit 10.1) for specific grant terms.
- Confirm the continued engagement of Cherry Bekaert, LLP as the independent auditor for the 2026 fiscal year.
- Note the significant number of broker non-votes (825,288) recorded for the director elections and the incentive plan proposal.